• Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

(970) 818-8343

info@cetya-therapeutics.com
Cetya TherapeuticsCetya Therapeutics
  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

About Cetya Therapeutics

This author hasn't written their bio yet.
Cetya Therapeutics has contributed 8 entries to our website, so far.

Cetya Therapeutics welcomes Dr. Anthony Wutoh to its Board of Directors

Cetya Therapeutics welcomes Dr. Anthony Wutoh to its Board of Directors

Jun 21, 2022

Provost & Chief Academic Officer of Howard University brings scientific experience and new perspectives on the consequences of sickle cell...

Cetya Therapeutics Appoints Ron Lowy to Board of Directors

Cetya Therapeutics Appoints Ron Lowy to Board of Directors

Jul 1, 2020

Adds extensive life science senior experience and transactional capability to the Board of Directors Fort Collins, CO, July 1, 2020...

Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102

Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102

Jun 11, 2020

Drug candidate active against EGFR and KRAS mutant lung cancer cell lines Fort Collins, CO, June xx, 2020 – Cetya...

Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors

Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors

Jan 29, 2020

Novel Chemistry Allows Conjugation of Largazole Analogs to Receptor Ligands or Other Cytotoxic Agents Fort Collins, CO, January 21, 2020...

Cetya Therapeutics Announces Phase II STTR Grant Award

Cetya Therapeutics Announces Phase II STTR Grant Award

Sep 23, 2019

 $1,000,000 NIH Grant will further development of Cetya’s HDAC inhibitor CT-101 for treatment of sickle cell disease   Fort Collins, CO,...

Cetya Therapeutics announces advanced industries award

Cetya Therapeutics announces advanced industries award

Dec 1, 2017

$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.

Cetya Therapeutics announces STTR grant

Cetya Therapeutics announces STTR grant

Sep 22, 2017

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.

Cetya Therapeutics announces seed round financing

Cetya Therapeutics announces seed round financing

May 8, 2017

$220,000 Round includes Canadian firm InSynchrony Ventures Inc Proceeds will advance oncology drug development. Fort Collins, CO, May 8, 2017...

Recent Posts

  • Cetya Therapeutics welcomes Dr. Anthony Wutoh to its Board of Directors
  • Cetya Therapeutics Appoints Ron Lowy to Board of Directors
  • Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102
  • Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors
  • Cetya Therapeutics Announces Phase II STTR Grant Award

Contact Us

We're currently offline. Send us an email and we'll get back to you, asap.

Send Message

Menu

  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

Contact

  • (303) 895-8216
  • info@cetya-therapeutics.com
Cetya Therapeutics, Inc.

320 E Vine Drive, Suite 128
Fort Collins, CO 80524

© 2018 · Cetya Therapeutics